Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: Two-year results from the COPERNICUS study

Ophthalmology

Volumn 121, Issue 7, 2014, Pages

  Heier, Jeffrey S ^a   Clark, W Lloyd ^b   Boyer, David S ^c   Brown, David M ^d   Vitti, Robert ^e   Berliner, Alyson J ^e   Kazmi, Husain ^e   Ma, Yu ^e   Stemper, Brigitte ^f,g   Zeitz, Oliver ^f,h   Sandbrink, Rupert ^f,i   Haller, Julia A ^j  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^b Palmetto Retina Center   (United States)

^c RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e REGENERON PHARMACEUTICALS INC   (United States)

^f BAYER PHARMA AG   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j WILLS EYE HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT;

ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; THROMBOEMBOLISM; TREATMENT DURATION; VISUAL ACUITY;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; QUESTIONNAIRES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84903819352     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.01.027     Document Type: Article

References (18)

1. R.L. McIntosh, S.L. Rogers, and L. Lim et al. Natural history of central retinal vein occlusion: an evidence-based systematic review Ophthalmology 117 2010 1113 1123
2. T.Y. Wong, and I.U. Scott Clinical practice. Retinal-vein occlusion N Engl J Med 363 2010 2135 2144
3. Central Vein Occlusion Study Group Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report Ophthalmology 102 1995 1425 1433
4. J.A. Haller, F. Bandello, and R. Belfort Jr. et al. Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results Ophthalmology 118 2011 2453 2460
5. SCORE Study Research Group A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5 Arch Ophthalmol 127 2009 1101 1114
6. Y. Tao, J. Hou, and Y.R. Jiang et al. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion Eye (Lond) 24 2010 810 815
7. C.J. Pournaras, E. Rungger-Brandle, and C.E. Riva et al. Regulation of retinal blood flow in health and disease Prog Retin Eye Res 27 2008 284 330
8. H. Noma, H. Funatsu, and T. Mimura et al. Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion Br J Ophthalmol 95 2011 788 792
9. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391 400 (Pubitemid 38618122)
10. D. Boyer, J. Heier, and D.M. Brown et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS Study Ophthalmology 119 2012 1024 1032
11. D.M. Brown, J.S. Heier, and W.L. Clark et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS Study Am J Ophthalmol 155 2013 429 437
12. F.G. Holz, J. Roider, and Y. Ogura et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study Br J Ophthalmol 97 2013 278 284
13. D.M. Brown, P.A. Campochiaro, R.P. Singh CRUISE Investigators Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1124 1133
14. N. Papadopoulos, J. Martin, and Q. Ruan et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2012 171 185
15. J.S. Heier, D.M. Brown, and V. Chong et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
16. D.V. Do, U. Schmidt-Erfurth, and V.H. Gonzalez et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema Ophthalmology 118 2011 1819 1826
17. P.A. Campochiaro, D.M. Brown, and C.C. Awh et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 118 2011 2041 2049
18. J.S. Heier, P.A. Campochiaro, and L. Yau et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial Ophthalmology 119 2012 802 809